83B Stock Overview
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
3SBio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.67 |
| 52 Week High | HK$0.93 |
| 52 Week Low | HK$0.55 |
| Beta | 0.78 |
| 1 Month Change | -0.75% |
| 3 Month Change | -0.75% |
| 1 Year Change | -21.76% |
| 3 Year Change | -13.64% |
| 5 Year Change | -59.20% |
| Change since IPO | -37.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 83B | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.1% | -0.2% | 0.5% |
| 1Y | -21.8% | -22.8% | 1.3% |
Return vs Industry: 83B exceeded the German Biotechs industry which returned -23% over the past year.
Return vs Market: 83B underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| 83B volatility | |
|---|---|
| 83B Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 83B has not had significant price volatility in the past 3 months.
Volatility Over Time: 83B's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 5,411 | Jing Lou | www.3sbio.com |
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer in combination with chemotherapy; Interferon, a human interferon a2a for injection; and Inleusin, for the treatment of renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer and tuberculosis. It also offers YISAIPU, the receptor-antibody fusion tumor necrosis factor inhibitor; Mendi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium; and Xenopax, a recombinant humanized anti-cd25 monoclonal antibody injection for prevention of acute rejection after renal transplantation.
3SBio Inc. Fundamentals Summary
| 83B fundamental statistics | |
|---|---|
| Market cap | €1.72b |
| Earnings (TTM) | €199.49m |
| Revenue (TTM) | €1.01b |
8.6x
P/E Ratio1.7x
P/S RatioIs 83B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 83B income statement (TTM) | |
|---|---|
| Revenue | CN¥7.82b |
| Cost of Revenue | CN¥1.17b |
| Gross Profit | CN¥6.64b |
| Other Expenses | CN¥5.09b |
| Earnings | CN¥1.55b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.65 |
| Gross Margin | 84.98% |
| Net Profit Margin | 19.82% |
| Debt/Equity Ratio | 29.1% |
How did 83B perform over the long term?
See historical performance and comparisonDividends
4.1%
Current Dividend Yield36%
Payout RatioDoes 83B pay a reliable dividends?
See 83B dividend history and benchmarks| 3SBio dividend dates | |
|---|---|
| Ex Dividend Date | Jul 22 2024 |
| Dividend Pay Date | Aug 05 2024 |
| Days until Ex dividend | 87 days |
| Days until Dividend pay date | 101 days |
Does 83B pay a reliable dividends?
See 83B dividend history and benchmarks